Singapore: Britain drugmaker AMCo recently announced the acquisition of pharmaceutical company, Boucher and Muir (BNM). Set up in 1957, BNM is an Australia-based specialty pharma company with sales in Australia, New Zealand and the Pacific Islands.

BNM sells medical products from vaccines to anesthetics, as well as more typical products such as solid dose tablets and capsules. The company has an excellent reputation for quality and reliability and works closely with government health departments in the Pacific Islands.

Mr John Beighton, chief executive officer of AMCo said, "Boucher and Muir has been our trusted partner in the Australasian region for the past decade and we are pleased to be able to acquire the company. It has a strong history of supplying niche medicines in the region and we will be looking to build on that as a cornerstone of AMCo's expansion in Australia, New Zealand and the surrounding geographies."

Mr David Frish, managing director of BNM said "We have had a great partnership with AMCo for the past decade and we are delighted to become part of the AMCo family. I look forward to working more closely with them as part of the team, and to bringing more AMCo niche medicines into local market."